Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
KDventures AB is a Sweden-based investment company specialized in life sciences. The company identifies and invests in innovative pharmaceutical projects and medical technology products originating from leading research institutions in the Nordic region. It provides capital to biotechnology firms and supports the development and commercialization of biotechnological products across areas such as oncology, infections and wound healing, women's health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, and implants. KDventures AB maintains a diversified portfolio spanning various development stages, from early research to commercialization, encompassing both listed and private life science projects. Through professional due diligence and active board engagement, it manages investments in subsidiaries like KDev Investments AB, which focuses on research, sales, and development in medicine. Headquartered in Solna, Sweden, KDventures AB plays a key role in the Nordic life sciences investment landscape, offering exposure to high-potential innovations in pharmaceuticals and biotech.
kr 0.27
+kr 0.00 (+0.19%)
Price from 6 days ago
The business is unprofitable at the operating level (-1249.67% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 9.1% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -kr 26M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 2M
▼ -9.1% YoY
Net Income (TTM)
-kr 194M
▼ -2293.0% YoY
Op. Margin
-1249.67%
▲ +457.7pp YoY
ROIC
-1.44%
▲ +0.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 26M
▲ +6.4% YoY
Op. Cash Flow (TTM)
-kr 26M
▲ +6.4% YoY
Net Debt
-kr 32M
Net Cash Position
Cash & Equiv.
kr 33M
3Y CAGR: -10.1%
Continue Research
KDventures AB (KDEV.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, KDventures AB scores 25/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
KDventures AB scores 25 out of 100 on Intrinsiqq's quality score, passing 2 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,249.7% operating margin and a -1.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh KDEV.XSTO's valuation and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.